Gleevec's Latest Approval is for Pediatric Cancer
FRIDAY, Jan. 25 (HealthDay News) -- The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said Friday.
Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) progresses rapidly if left untreated. Gleevec, among a class of drugs called tyrosine kinase inhibitors, blocks proteins that promote development of cancer cells, the FDA said in a news release.
The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.
Gleevec was first approved in 2001 to treat a form of chronic myeloid leukemia, and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.
To learn more about Gleevec, visit the U.S. National Cancer Institute.
-- Scott Roberts
Glossary of Leukemia TermsView All Terms
Leukemia Related Links from WrongDiagnosis
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Down Syndrome
- Epstein-Barr Virus
- Fanconi's Syndrome
We'd like your feedback.
Are you a cancer patient, cancer survivor or a caregiver for a cancer patient? Please complete a very brief survey to improve patient care.
A survey will be presented to you after you finish viewing our Leukemia content.
Take a Personalized Health Test
Leukemia Related Conditions
Health News TodayFeed
- Gene Mutations Tied to Leukemia Rise With Age, Study Finds02/26/2015
- Eczema Cream for Children Not a Cancer Risk, Study Finds02/18/2015
- Breast Cancer Chemo Tied to Small But Significant Leukemia Risk12/24/2014
- Screening Test Approved for Viruses That Cause Blood Cancer12/11/2014
- Hodgkin Lymphoma Treatment Shows Promise in Small Trial12/08/2014
- View More Leukemia News